Sean P Pitroda
Overview
Explore the profile of Sean P Pitroda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1877
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arshad M, Lynch C, Katipally R, Pitroda S, Weichselbaum R
Oncotarget
. 2025 Mar;
16:163-166.
PMID: 40079896
No abstract available.
2.
Huang D, Lynch C, Serra L, Sweis R, Chang P, Stadler W, et al.
Clin Transl Radiat Oncol
. 2024 Nov;
49:100879.
PMID: 39529961
Background And Purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic...
3.
Bestvina C, Hara J, Karrison T, Bowar B, Chin J, Garassino M, et al.
Clin Lung Cancer
. 2024 Sep;
25(8):e448-e452.
PMID: 39242330
Background: Immunotherapy in combination with chemotherapy is first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Growing evidence suggests that radiation, specifically stereotactic body radiation therapy (SBRT), may enhance...
4.
Spurr L, Pitroda S
Sci Rep
. 2024 Aug;
14(1):19375.
PMID: 39169079
Recent studies have linked elevated tumor aneuploidy to anti-tumor immune suppression and adverse survival following immunotherapy. Herein, we provide supportive evidence for tumor aneuploidy as a biomarker of response to...
5.
Lynch C, Korpics M, Katipally R, Bestvina C, Pitroda S, Patel J, et al.
Eur J Cancer
. 2024 Aug;
209:114264.
PMID: 39106643
Background: Stereotactic body radiotherapy (SBRT) is safe and effective for treatment of extracranial metastatic disease, but its safety when combined with immune checkpoint inhibitors (ICI) has not yet been comprehensively...
6.
Lynch C, Pitroda S, Weichselbaum R
Lancet Oncol
. 2024 Aug;
25(8):e352-e362.
PMID: 39089313
Radiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune...
7.
Lynch C, Arshad M, Katipally R, Pitroda S, Weichselbaum R
J Clin Oncol
. 2024 Jul;
42(29):3387-3391.
PMID: 39038267
Sharing the burden of low-volume metastatic cancer between ICB and local treatments.
8.
Rajeev-Kumar G, Pitroda S, Szmulewitz R, Skolarus T, Eggener S, Liauw S
Clin Genitourin Cancer
. 2024 May;
22(4):102103.
PMID: 38781786
Background: We previously reported that for men undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT) for prostate cancer, substitution of LHRH-agonists with 5-α- reductase inhibitors (5-ARIs) led to...
9.
Wang L, Lynch C, Pitroda S, Piffko A, Yang K, Huser A, et al.
J Exp Med
. 2024 May;
221(7).
PMID: 38771260
The majority of cancer patients receive radiotherapy during the course of treatment, delivered with curative intent for local tumor control or as part of a multimodality regimen aimed at eliminating...
10.
Hou Y, Yang K, Wang L, Wang J, Huang X, Piffko A, et al.
Clin Cancer Res
. 2024 Mar;
30(9):1945-1958.
PMID: 38427437
Purpose: Radiotherapy (RT) is a widely employed anticancer treatment. Emerging evidence suggests that RT can elicit both tumor-inhibiting and tumor-promoting immune effects. The purpose of this study is to investigate...